文献速递介入外周血管儿科影像DSA

儿童外科肠系膜门静脉与门体分流道功能障碍的血管内治疗

Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients.
PubMed 文献 · Pediatr Radiol · 2019-07-04

单中心回顾性研究纳入20例儿科患者,对13条脾肾、3条肠系膜-Rex、2条肠腔、2条脾腔分流道行52次血管内介入治疗。狭窄分流道技术成功率100%,闭塞分流道为66.7%;1个月原发通畅率17/17(100%),24个月降至4/10(40%),但联合原发与辅助原发通畅率达100%。

要点

  • 狭窄性分流道血管内治疗技术成功率100%,闭塞性分流道为66.7%。
  • 术后1个月原发通畅率17/17(100%),24个月为4/10(40%)。
  • 经血管内再干预后,全部分流道达到原发或辅助原发通畅。

核心结论

  • 功能障碍的门体外科分流道可通过血管内方法有效管理;虽多需再干预,但原发通畅与辅助原发通畅合计率极佳。

研究设计与样本

  • 单中心回顾性研究,纳入2010至2018年在一家三级儿童医院接受血管内治疗的20例患儿(男11例、女9例;平均年龄8.25岁,范围1.3–17岁),共52次介入操作,涉及13条脾肾、3条肠系膜-Rex、2条肠腔和2条脾腔分流道。

诊断标准与关键数值

  • 技术成功定义为成功插管并对分流道实施介入,且静脉造影显示血流改善。

临床应用与阅片要点

  • 对狭窄性分流道行血管内治疗的技术成功率为100%,对闭塞性分流道为66.7%。
  • 术后1个月原发通畅率17/17(100%),6个月10/16(62.5%),12个月7/15(46.7%),24个月4/10(40%)。
  • 每名患儿平均再干预1.9次(标准差3.1),狭窄性与闭塞性分流道间无差异(P=0.24)。
  • 初次技术成功后无分流道闭塞病例,全部分流道经血管内再干预达到原发或辅助原发通畅。
  • 无再干预中位时间为387天(标准差821天)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Published data describing the endovascular treatment of dysfunctional mesoportal and portosystemic shunts in the pediatric population are limited.

OBJECTIVE: We sought to describe the treatment and follow-up of such shunts managed by interventional radiology at a single pediatric hospital. We hypothesized that stenotic and occluded pediatric portosystemic and mesoportal shunts can be maintained patent by interventional radiology in the moderate term.

MATERIALS AND METHODS: We conducted a single-center retrospective study at a tertiary pediatric hospital. We included children with surgical mesoportal (meso-Rex) or portosystemic (mesocaval, splenorenal or splenocaval) shunts treated with attempted angioplasty or stenting from 2010 to 2018. Technical success was defined as catheterization and intervention upon the shunt with venographic evidence of flow improvement. The primary outcome variables were shunt patency at 1 month, 6 months, 12 months and 24 months post-procedure and freedom from reintervention.

RESULTS: Twenty pediatric patients (11 boys, 9 girls; mean age 8.25 years, range 1.3-17 years) met inclusion criteria. Fifty-two interventions (primary and reintervention) on 13 splenorenal, 3 meso-Rex, 2 mesocaval and 2 splenocaval shunts were performed because of evidence of shunt failure, including gastrointestinal bleeding, hypersplenism, or radiographic evidence of a flow defect. The 11 stenotic shunts were treated with 100% technical success, while the remaining 9 occluded shunts were treated with 66.7% technical success. The mean number of reinterventions was 1.9 (standard deviation [SD] = 3.1) per child, which did not differ between stenotic and occluded shunts (P=0.24). Primary patency at 1-month, 6-month, 12-month and 24-months follow-up visits was 17/17 (100%), 10/16 (62.5%), 7/15 (46.7%) and 4/10 (40%), respectively. However, 100% of shunts were either primary patent or primary-assisted patent by endovascular reintervention. There were no cases of shunt occlusion following initial technical success. Finally, the median freedom from reintervention duration was 387 days (SD=821 days).

CONCLUSION: Dysfunctional portosystemic surgical shunts are effectively managed by endovascular methods. While many shunts require reintervention, combined primary patency and assisted primary patency rates are excellent.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Stein EJ, Shivaram GM, Koo KSH, et al. Endovascular treatment of surgical mesoportal and portosystemic shunt dysfunction in pediatric patients. Pediatr Radiol. 2019. PMID: 31273428. doi:10.1007/s00247-019-04458-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。